Please ensure Javascript is enabled for purposes of website accessibility

Why 111 Stock Soared, Then Dropped Thursday

By Howard Smith - Feb 11, 2021 at 1:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Chinese healthcare platform is being compared to some successful U.S. peers.

What happened

Shares of 111 (YI 20.75%) soared 76% on Thursday before reversing course with a decline of 5.4% as of 12:45 p.m. EST. Even with the reversal, the Chinese online healthcare platform stock has more than doubled in the past week and has year-to-date gains greater than 250%. 

YI Chart

YI data by YCharts

So what

Ten-year-old 111 operates a leading Chinese digital and mobile healthcare platform. The telehealth segment has gained popularity with the success of Teledoc Health (TDOC 6.94%) in the U.S., and this Chinese company is aiming to follow that path. Investors appear to now be looking for the next Teledoc.

patient online with doctor for telemedicine

Image source: Getty Images.

Now what

111 isn't nearly the size of Teledoc Health, with a market capitalization of around $2 billion. Teledoc has grown to a $40 billion company. But the demographics in China are compelling for the sector. 111 says it is the first Chinese telemedicine company listed publicly in the U.S. 

The company's business segments include an online pharmacy platform for businesses and consumers, and online doctor care. The company completed two rounds of funding in the second half of 2020 for the purpose of expanding the business, for a total of almost $150 million. 

At the time of the most recent investment round, in Dec. 2020, Mr. Junling Liu, 111 co-founder, chairman, and CEO, said in a statement, "Our biggest challenge today is responding to the overwhelming number of opportunities with which we are being confronted."

Many investors like to look for the next big thing. And China has a population that could support this industry, if it fits culturally. For U.S. investors, my advice would be to tread carefully, do the research, and treat any potential investment in 111 as speculative. 

This article represents the opinion of the writer(s), who may disagree with the "official" recommendation position of a Motley Fool premium advisory service. We're motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

111, Inc. Stock Quote
111, Inc.
$1.92 (20.75%) $0.33
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$35.77 (6.94%) $2.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.